Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Curvebeam AI Ltd. ( (AU:CVB) ) has shared an announcement.
CurveBeam AI has expanded its commercial agreement with Stryker to include Australia and New Zealand, focusing on increasing demand for its HiRise weight-bearing CT scanner through surgeon education and promotion. This exclusive agreement, initially set for three years, capitalizes on Stryker’s sales organization to enhance market reach and is seen as a significant expansion opportunity for CurveBeam AI in these regions, aiming to place scanners in imaging centers and hospitals.
More about Curvebeam AI Ltd.
CurveBeam AI Limited is a company that develops, manufactures, and sells specialized medical imaging CT scanners and AI SaaS-based clinical assessment solutions. The company’s flagship product, the HiRise CT scanner, offers both weight-bearing and non-weight-bearing CT scans, providing advantages over traditional CT or MRI devices. CurveBeam AI operates with over 70 employees, with its corporate office and AI functions based in Melbourne, Australia, and global operations headquarters in Hatfield, Pennsylvania, USA.
YTD Price Performance: -14.81%
Average Trading Volume: 254,487
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$44.83M
See more insights into CVB stock on TipRanks’ Stock Analysis page.
